This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

Daniel, stem cell recipient

Impact Report and Financial Statements

Year ending 31 December 2022

Our Vision

To delete blood cancer.

Our Mission

To give as many blood cancer patients as possible a second chance at life.

Our Purpose

To raise awareness of blood cancer and blood disorders, recruit and retain potential blood stem cell donors to provide a second chance at life, raise funds to match donor registration costs, provide access to transplantation for more blood cancer patients, and improve blood cancer therapies by our own research.

Contents
CountryManager’s introduction	03
Daniel’s blood cancer diagnosis	04
The search for a match	06
Coveringcosts	08
Donor evaluation	10
Stem cell donation	12
Daniel today	16
Thankyou	18
Trustees’ Report for theyear ended 31 December 2022	20
Trustees’ responsibilities statement for theyear ended 31 December 2022	25
Independent auditors’ report	26
Statement of fnancial activities	30
Waysyou can support us	54

Country Manager’s introduction

In a year where the world continued to face a number of global challenges, it has been especially poignant to see the true meaning of community and the spirit of generosity triumph. As a global organisation we are able to see the health and social inequalities highlighted more recently by the cost of living crisis and how this causes uncertainty and anguish across countries, cities, villages and communities the world over. Seeing people stand up to support others in crisis reinforced the ethos behind which DKMS was founded: to always strive to provide second chances.

As cancer continues to be a leading cause of death worldwide, in 2022 DKMS UK achieved 325 stem cell donations and remains the largest contributor to the aligned UK stem cell register. As we strive towards reaching the one million donors mark, one of our main focuses continues to be our commitment to diversify the register, for which we have already achieved over a 13% increase in the number of donors from minority ethnic backgrounds from 2021 to 2022.

Seeing communities come together to achieve a collective goal was never more apparent than in the story of Daniel whose journey from blood cancer diagnosis to blood stem cell transplant can be followed throughout this report. Diagnosed with acute myeloid leukaemia in 2022, sharing his search to find a matching donor contributed to us hosting over 300 in-person donor recruitment events across the UK last year and also saw us form new corporate partnerships to help spread awareness of the register far and wide. Having achieved

over 1,500 registrations online and offline, Daniel thankfully found a matching donor from Germany.

The aim of this report is to highlight the achievements the organisation has experienced over the past year, with the example of Daniel being just one of the many patients we have worked with who have been successful in finding their match. We are aware now more than ever that the fight against blood cancer is not yet won, and that more work is needed to ensure we are able to support the hundreds of patients like Daniel in the UK looking for their second chance at life. Therefore, we will continue our work with zeal and with the support of our remarkable volunteers, supporters and staff we will continue to bring hope to those with blood cancer and their loved ones. Above all, we continue to remain in awe of all the seemingly ordinary people who make the very special choice to register to become a blood stem cell donor for DKMS, and who go on to provide a patient in need with the most extraordinary gift ever.

“We will continue our work with zeal and with the support of our remarkable volunteers, supporters and staff.”

3 3

Patient diagnosis

Search for a match

Covering costs

Donor evaluation

Stem cell donation

06 Daniel today

01 Daniel’s blood cancer diagnosis

Every year, more than 2,400 people in the UK are in need of a blood stem cell donation from an unrelated donor. However, finding a matching donor is like finding a needle in a haystack, which means that for some patients there won’t be a match readily available on the stem cell donor register.

Last year, as part of our ongoing donor recruitment efforts, DKMS UK worked with 28 new patients with blood cancer and blood disorders to help them find a matching donor. One of these was Daniel, based in Northern Ireland.

York on St. Patrick’s Day, he was hospitalised and diagnosed with AML two days later. Suddenly, there was no more rugby training and trumpet practice, Daniel was fighting for his life.

The diagnosis took the family completely by surprise. Anne Delargy, Daniel’s mother, explains: “There is absolutely no blood cancer history in our family! Cancer is an awfully random thing which is why it is so important to encourage as many people as possible to register with DKMS as the need for stem cell donors is huge. It can happen to anybody.

Daniel was diagnosed with acute myeloid leukaemia (AML) in May 2022 at just 14 years old. At the time of his diagnosis there was no match available for him on the global stem cell register.

Daniel spent his last weekend before being diagnosed with blood cancer performing at a local jazz festival. On the Monday he passed a singing exam, and had his rugby training and orchestra practice front of mind. But, instead of joining his peers to perform at a once-ina-lifetime concert at Carnegie Hall in New

“I suppose it takes everybody by surprise, but if your kid has an exceptionally good diet, loves fruit and vegetables, is good at sports, you wouldn’t think that he is in a risk group for getting cancer. I never foresaw this coming to my door.”

AML had to be treated fairly quickly with a high dosage of chemotherapy. Daniel’s first session lasted for 10 days and included about 25 different drugs just at that initial stage. He was very unwell and desperate to get out of hospital, but the only way to totally beat the cancer for Daniel, as for many more like him, was to receive a matching stem cell transplant. He desperately needed this transplant to help his bone marrow to produce new healthy blood cells on its own.

While Daniel was battling cancer in the hospital, his loved ones launched the #DoItForDaniel appeal, working with DKMS UK to encourage people to sign up to the blood stem cell register.

Blood cancer is the fifth most common cancer in the UK

Daniel’s family was utterly grateful to see so many people from their local community come forward and try to save Daniel. With all the help, the Greer family registered over 1,500 new donors to the blood stem cell register, providing many more chances for someone to find a match, receive a donation and recover from cancer.

Blood cancer is the fifth most common cancer in the UK and accounts for nearly half of all cancer diagnoses in children. Daniel’s story is proof that we need more blood stem cell donors. It’s evidence of the impact that can be achieved when communities and businesses work together towards DKMS’ shared goal of finding a match for every person with blood cancer or a blood disorder.

“No one would ever suspect that this active boy was sick with leukaemia. It was completely unexpected and new to us. I have never personally known someone who was fighting with cancer. In my mind leukaemia was something to affect mainly babies or younger children, not a healthy teenage boy.”

Anne, Daniel’s mother

Patient diagnosis

----- Start of picture text -----
02
----- End of picture text -----

Search for a match

Covering costs

Donor evaluation

Stem cell donation

06 Daniel today

The search 02 for a match

When someone reaches out to DKMS for support in finding a donor, our dedicated patient campaign team will develop an appeal to encourage potential donors to sign up to the stem cell register. This appeal will be shared far and wide in the hope of finding a matching donor.

Daniel’s appeal #DoItForDaniel illustrated what is possible when we are able to work closely with a family to find new potential donors.

Beyond Daniel’s appeal, DKMS’ donor recruitment team worked tirelessly through the year to register as many potential donors as possible, so that every patient searching for a match could have the best possible chance of finding one. There were over 300 in-person donor recruitment events across the UK in 2022, including 59 corporate events at workplaces – the Department for Education ran a series of ‘swab-along’ events at their different sites, while Siemens and TalkTalk held registration events at their offices.

The family felt comfortable to reach out to their local community with Daniel’s story, which led to several local events arranged by community members and businesses. DKMS UK also partnered with McKeevers Chemists, a chain of pharmacies which was able to offer in-person donor registration at some of its Northern Ireland locations. McKeevers also arranged a registration event at a Belfast Giants ice hockey game at the SSE Arena in Belfast where 88 new potential donors were registered. In 2023, McKeevers was awarded the ‘Working in Partnership’ award at the Pharmacy in Focus Awards, a significant accolade and a wonderful testament to the company’s work with DKMS.

One of the most heart-warming corporate events of 2022 was organised by Heena, an employee at management consultant Deloitte. She felt compelled to do something when she realised that she knew a DKMS patient, and also one of her Deloitte colleagues, Richard, had survived blood cancer thanks to a stem cell donation. Heena approached DKMS UK and together we came up with the idea of swabbing as many people as possible at a regional conference Deloitte was holding in London.

Over 300 in-person donation events in 2022

Daniel’s campaign also reached beyond Northern Ireland through a family connection, inspiring footballer Jimmy Dunne to rally his club, Queens Park Rangers in London, to hold a registration event at its ground on match day. The club also released a video featuring Jimmy appealing to the wider football community to register as donors, in the hope of someone being Daniel’s match. This appeal was widely shared through news sites such as The Independent and The Irish Times, and also featured on talkSPORT radio. The drive was supported by two members of staff and three volunteers. On match day, DKMS signed up 90 potential blood stem cell donors.

“It was like conducting the most vital orchestra. It was an emotional event as delegates clearly realised the impact such a simple act could have.”

With the football community behind Daniel’s appeal, we were also able to register more than 1,500 new potential blood stem cell donors who were inspired by his story. This included 1,096 online registrations driven by social media.

Louise, DKMS Donor Recruitment Manager

Richard took to the stage to share his story and explained how without a stem cell donation, he wouldn’t be alive today. DKMS Donor Recruitment Manager Louise, who also attended, bravely shared her own story of the loss of her husband from blood cancer and the devastating effect it had on her and her children. With virtually the whole audience in tears, Lou called on them to take action there and then. Eligible delegates were asked to take out the swab sticks from the swab packs they had been given and complete their registrations together.

76,294

How many people we registered last year

£40 to register each new donor

Deloitte went above and beyond to encourage its employees to join the donor register. Not only did more than 100 employees register on the day of the company’s conference, but Deloitte also donated £4,000 towards the cost of those registrations. It costs DKMS £40 to register each new donor, so all those inspired to sign up at the event were covered by Deloitte’s generous contribution. This type of corporate event helps to build community in an organisation, benefits a company brand, and thanks to Deloitte’s input was also a huge help towards DKMS’ goal of registering more donors at little cost to the charity. For these reasons, corporate events are some of the most powerful ways that DKMS builds its donor register.

1,531

How many people registered for Daniel’s appeal (online and offline)

01 Patient diagnosis

02 Search for a match

----- Start of picture text -----
03
----- End of picture text -----

Covering costs

04 Donor evaluation

05 Stem cell donation

06 Daniel today

Covering 03 costs

This year we were thrilled to see the DKMS community stepping up to the challenge of raising money to help cover the cost of donor registrations. From corporate partnerships to everyday giving, triathletes to daredevils, there was a lot of fundraising to celebrate.

Alongside their registration events, Daniel’s supporters also organised sponsored concerts and chose DKMS UK as their charity of the year (see below). It costs DKMS UK £40 to register each new potential donor which is why we are always looking for fundraisers and corporate partners to support our work.

“DKMS UK has been blown away by the support we have received from companies, fundraisers and supporters” says Caroline Richardson, Head of Fundraising. “In addition to the many corporate events that took place up and down the country, over 400 people gave a regular gift and 87 people ran their hearts out for us. Twenty one people put on their hiking boots and walked in support and 15 adrenaline junkies undertook a crazy event. Eleven people did something significant in memory of someone special who lost their fight against a blood cancer or a blood disorder. In total we had 171 fundraising events across the year and 110 people celebrated their birthdays with us. To each and every one of you we thank you for kindness and dedication to furthering the work of DKMS, helping us to fund second chances at life. We really couldn’t do it without you!”

Charity of the Year: Education Authority Music Service, Northern Ireland

What DKMS can achieve with your financial support

Never is the power of music more resonant than when it comes from the heart. The Education Authority Music Service (EAMS) in Northern Ireland demonstrated this when it chose DKMS as its charity of the year in support of the #DoItForDaniel campaign.

Raise awareness of and register more donors to the blood stem cell register

Cover the cost of donor registrations

Daniel, part of EAMS orchestra’s horn section, had to give up playing when he was diagnosed with blood cancer and underwent treatment. His fellow young musicians were eager to come to his aid and supported Daniel’s search for a donor match by putting on a series of concerts. In 2022 they raised a total of £2,636, with more fundraising concerts planned for 2023.

Support more patients to find their potentially lifesaving match

Engage with more corporate partners and their employees to deliver workshops, fundraising activities and registration events

How our registration costs are split up

----- Start of picture text -----
£13.20 £1.22
Swab kit Fulfilment
& Postage
Total
£40
£22.95 £2.63
Laboratory Education
HLA typing & Engagement
----- End of picture text -----

Campaigns

Queen’s Jubilee: The first in our ongoing series of ‘When I grow up’ fundraising campaigns, we asked our community to help more little princesses, like Esha and Livia, who were both diagnosed with acute myeloid leukaemia (AML), grow up to be queens by helping to cover the cost of new donor registrations.

What do you want to be when you grow up?:

In the second part of our campaign series, we focused on Josie and Shahera, who both dream of being doctors. Their dreams are currently on hold while they search for a donor, but with the help of the money this campaign raised, we can continue to support their search.

Swabtember: A new campaign which was launched in September 2022 to coincide with Blood Cancer Awareness Month. Swabtember is a virtual activity that challenged participants to collectively, as a team, or individually travel 635 miles, the journey each of our swab kits takes from the UK to our laboratories in Germany.

“We do not receive any government funding so depend on generous donations from our amazing supports, individuals, fundraisers and companies, to recruit more people to the register. It costs £40 to register each potential lifesaver so your money is vital to help us save more lives.”

Caroline Richardson, Head of Fundraising

Corporates - vital collaborations

In 2022, DKMS:

Was the chosen charity of the year for three organisations; Toton Banks Road School, Yarm Methodist Church and Broome Manor Golf Club Wiltshire Ladies Team

corporate registration events organised

companies to the £2k Club, a club of corporate supporters whose contribution of £2,000 will give membership of the club for one year

----- Start of picture text -----
01
Patient
diagnosis
----- End of picture text -----

----- Start of picture text -----
02
----- End of picture text -----

Search for a match

03 Covering costs

----- Start of picture text -----
04
----- End of picture text -----

Donor evaluation

05 Stem cell donation

06 Daniel today

Donor 04 evaluation

“It took us several months to find Daniel a donor. We were initially told of two potential matches that fell through, but luckily, the third time was a success and we got confirmation that our son was paired with a young lady from Germany.” Anne, Daniel’s mother

Daniel was fortunate to find his matching donor, but for many patients, the search continues.

matched with a donor from the same ethnic background but, unfortunately, people with minority ethnic backgrounds still only have a 37% chance of finding a matching blood stem cell donor, compared to a 72% chance for those from a white Caucasian background. While DKMS UK is currently the most diverse and largest contributor to the UK aligned stem cell register, we are continuing outreach work among the UK’s diverse range of minority ethnic communities to increase the possibility of finding a match for every person in need. In 2022, 476 people in the UK received stem cell transplants from DKMS donors from around the world.

When a person joins the donor database, their cheek swabs are sent to our cuttingedge laboratory where the donor’s human leukocyte antigen (HLA) tissue type is added to the global DKMS stem cell register.

Our state-of-the-art laboratory

For more than 20 years, the DKMS Life Science Lab in Dresden, Germany, has repeatedly set new standards in genotyping. An accredited clinical laboratory and a clinical research centre are attached to the lab, with a team of experts in the fields of genetics, biotechnology and bioinformatics working to ensure the best possible high-resolution typing. This team is making continuous scientific progress in improving donor profiling. The better and more detailed the profiles, the more patients will be able to find their match - and this process happens much faster than in previous years, which can make a huge difference to the patients’ treatment.

Through this state-of-the-art-laboratory, DKMS is able to provide the best quality typing for the lowest possible cost.

A real strength of DKMS’ international database is the growing diversification of donors on the register. By being based in Europe, Africa, North and South America and Asia, DKMS is able to increase the number of second chances at life for patients from a diverse range of ethnic backgrounds. A patient is much more likely to be

Contributors to the aligned UK stem cell registry 2022

----- Start of picture text -----
17% 3%
NHSBT WBMDR
42% 38%
DKMS Anthony Nolan
----- End of picture text -----*

NHSBT: NHS Blood and Transplant *WBMDR: Welsh Bone Marrow Donor Registry

Donors on the DKMS UK register by ethnicity

	2022	2021	% increase
African-	14,165	13,076	8.3%
Caribbean
Asian	84,671	71,987	17.6%
Middle Eastern/	17,098	15,108	13.2%
Mediterranean
Mixed	20,150	17,750	13.5%
background
British, Irish	785,356	685,851	14.5%
and European
Other	47,128	43,625	8.0%

TOTAL 968,568 847,397

----- Start of picture text -----
01
----- End of picture text -----

Patient diagnosis

----- Start of picture text -----
02
----- End of picture text -----

Search for a match

Covering costs

Stem cell 05 donation

Finding a matching stem cell donor is about as rare as finding a needle in a haystack. That’s why we call our donors lifesavers-in-waiting, and why we need so many people on the register. In 2022, DKMS donors provided over 7,700 donations globally to patients on all continents.

so that they can share their experience with others who understand what it’s like donating to a stranger.

In order to provide more lifesaving matches, DKMS not only recruits donors to the register but also supports them at every step of their lifesaving journey. From explaining the medical process during the initial contact to arranging accommodation and transport at no cost to the donor, DKMS provides support throughout the process.

Joe, who is from the same city in Northern Ireland as Daniel, donated his stem cells via PBSC donation in June 2022 – around the same time that Daniel received his diagnosis.

“I’m not 100% sure where I heard about DKMS, but I think it was on Children in Need. I remember seeing that and thinking it’s only a swab in the mouth to get my name on the register. So, I signed up. I then didn’t hear anything until seven years later!”

At the end of 2022, our post-donation survey showed that 99% of donors, regardless of whether they had donated via peripheral blood stem cell (PBSC) or bone marrow donation, would be willing to donate again. DKMS UK also invites donors to join a Donor Club,

04 Donor evaluation

----- Start of picture text -----
05
----- End of picture text -----

Stem cell donation

06 Daniel today

“I received a phone call from a number I didn’t recognise. I normally wouldn’t answer the phone when it’s a strange number, but this day I picked up and it was a nice man telling me I was a potential match.

“I was excited. It’s good to be able to help somebody, even if you don’t know them, to give somebody an extra chance of living. Right now, I’m becoming a fire fighter as well. I joined the fire service to be able to help save lives. This was a great opportunity.

“The donation took place in London. First of all, I travelled there to have my medical examination. There was a period of back and forth because at my first examination my blood pressure was high. I had got lost on the way and I also hate needles and having blood samples taken, so I needed a letter from my GP to clear things up. I went back for a second medical examination which was all clear and was then given the G-CSF (a naturally occurring growth hormone that stimulates the production of stem cells in the blood) injections to

take home and use prior to going back for the actual donation day.”

“My only real side effect from the injections was I got a very sore head. Emotionally, I suppose when you’re taking them and you know you’re producing more stem cells and you’re going to be giving them to somebody else, it’s quite a big feeling that you’re doing something to help somebody, even if it’s a stranger. You’re potentially saving their life. The pros outweigh the cons.

“I travelled over on the donation day back to The London Clinic and the staff are all very nice. I was starting to get a bit sweaty when they were putting my needles in, but they were brilliant and just what I needed. I felt fine and it only took a few hours.

“After the donation, I felt great. I was back at work a couple of days later. There were no side effects whatsoever. If that’s all it is at the end of the day to save someone’s life it’s well worth it.

“The DKMS team were brilliant. They’re very friendly and communicative. I wasn’t waiting on phone calls and knew what was going on. It was very informal and they would ring me with any updates which was great.

“Around 10% of donations are carried out by bone marrow harvest. The patient team will choose which donation method would be most beneficial for the patient based on a variety of factors, including the patient’s medical diagnosis, their current condition and the stage of the disease. A bone marrow harvest is a procedure carried out under general anaesthetic, in which a doctor makes two small incisions in the donor’s lower back and removes bone marrow from their pelvic bone using a needle.”

Louise Bailey, Team Lead, Work Up, DKMS UK

----- Start of picture text -----
01
----- End of picture text -----

----- Start of picture text -----
Patient
diagnosis
----- End of picture text -----

----- Start of picture text -----
02
Search for
a match
----- End of picture text -----

----- Start of picture text -----
03
Covering
costs
----- End of picture text -----

“Looking back on it, I would definitely do it again. I’d do it every month if I could save somebody.

“It was a bit of a coincidence that I got called up when Daniel’s appeal had just started. Other local people were targeted by it, just like I was, but I had donated already. I was on the register for seven years and didn’t hear anything from DKMS but as a coincidence a local family needed help and DKMS were there for them. It was great to be able to help out at the same time. I was excited and I was hoping that maybe I was the match for Daniel, but it turned out I wasn’t. But it’s great to be able to connect myself with Daniel regardless. Somebody though needed it then and it made me more aware and emotional that I was able to help.

“At the time, I talked to family members and people at work who were talking about Daniel, and I was able to say, ‘I’m doing that! I don’t I don’t think it’s for Daniel, I’m doing a stem cell donation for somebody’. I got arm bands sent over and started handing them out to colleagues to help promote the register.

“I left some with a friend who works at a local sports shop and he helped hand some out.

“If someone said they were thinking about becoming a donor, I would tell them 100% don’t hesitate or think that you shouldn’t be doing it because it’s well, well worth it. It’s probably the most amazing thing you’ll ever do in your life.

“If I had the chance to speak to Daniel’s family, I’d tell them they did a great job with promoting DKMS and they had great fundraising ideas. The passion that they had for fighting for donors, it was unbelievable. I mean of course they would do it. Anyone would do it. They were fighting for life.

“Most importantly, it paid off. That’s the bottom line. Daniel found his donor and he’s recovering. Plus, a lot of people signed up to the register because of him, so even if they’re not Daniel’s match there’s thousands more people that are on the register that could potentially save someone else’s life.”

Global breakdown: where DKMS UK sent stem cells in 2022

----- Start of picture text -----
04
Donor
evaluation
----- End of picture text -----

05 Stem cell donation

----- Start of picture text -----
06
Daniel
today
----- End of picture text -----

----- Start of picture text -----
114
Europe
83
106
UK 20
North America
Asia
3 4 16
South America Africa Oceania
----- End of picture text -----

476 UK patients received a stem cell transplant from DKMS in 2022

•- KMSD YOU COULD BEA LIFESAVER ,V , Sign up today to become a potential blood stem cell donor dkms.org.uk 15

01 Patient diagnosis

----- Start of picture text -----
02
----- End of picture text -----

Search for a match

03 Covering costs

04 Donor evaluation

05 Stem cell donation

06 Daniel today

06 Daniel today

Daniel is just one of the 28 newly diagnosed patients from the UK supported by DKMS UK in 2022. We also shared various international appeals, like that for 13-year-old Amelia from Poland who was diagnosed with leukaemia and seven-month-old Javi from the US who was diagnosed with acute lymphoblastic leukaemia (ALL).

Finding a matching stem cell donor can be difficult, regardless of the patient’s genetic background. DKMS’ work is far from finished, but with the support of our fundraisers, partners and donors, we can continue to give hope to those with blood cancer and their loved ones.

Thankfully, Daniel’s perfect match was found in October 2022, and he successfully received his stem cell donation a month later. Daniel was well enough to fly home from Bristol Royal Hospital for children just before Christmas. All the family know about the donor is that she’s a young lady from Germany. Daniel sent a Christmas card to her wishing her a healthy New Year and got a reply in which she called him her ‘genetic twin’. Daniel is hoping to meet his donor one day to thank her in person for giving him a chance for the future.

Although the transplant was successful, the road to recovery has been long and full of bumps along the way. Daniel had a very rough February and early March, so it was decided to transfer him back to Bristol Royal Hospital’s Children Haematology Department, where he received his transplant. He stayed there until he overcame Graft versus Host Disease (GvHD), a systemic disorder that occurs when the graft’s immune cells recognise the host as foreign and attack the recipient’s body cells.

Nevertheless, Daniel and his family stay hopeful: the blood tests show that the donor transplant was a success. What is next for Daniel is to overcome any further posttransplant complications. He is not living his old life just yet, but he and his family hope he’ll be back at home, picking up the trumpet and scoring tries in the near future. They are eternally grateful to his donor and want to ensure other families whose lives have been shaken by a blood cancer diagnosis, are able to find their own generous stranger to save their loved ones.

Daniel’s diagnosis had an enormous effect not just on his life, but on the lives of everyone in his family, which is why his mother has become an active advocate to raise awareness about the donor registration process and encourage more people to join. Anne says, “If I could say one thing to nudge people to sign up it would be: it could be you. You never know with cancer. If you were happy to accept a donation for yourself or for somebody else in your family, then really you should be on that donor list. It’s not a one-way street.”

Anne believes one of the main reasons people do not sign up is the lack of understanding of the process of stem cell transplants. Even though she is a doctor, Anne didn’t realise how easy the process actually was. In reality, around 90% of all donations are made through a method called peripheral blood stem cell (PBSC) donation, which is similar to the process of giving blood. In return, someone is given a chance to survive cancer.

It is vital to remember that Daniel’s story is not a single case. In spring 2023, DKMS has just started working with another young patient named Bobby who is from the same area of Northern Ireland as Daniel’s family, and once again the local community is ready to come to his aid. The impact of Daniel’s story, and all the donors who DKMS was able to register through his appeal in 2022, doesn’t end with Daniel’s transplant. It will continue to be seen through the increased awareness of the stem cell donor register and through those who will register as a result.

This is why it is so important to raise awareness about the process of blood stem cell donation to increase the number of informed sign-ups. Every registration could give someone a second chance at life.

In April 2023, the first donor who registered as a result of Daniel’s appeal went on to donate their stem cells.

Thank you

With the help of other organisations who support our mission to delete blood cancer, DKMS is able to work more effectively, finance more donor registrations, and support more patients and donors.

Thank you to all the trusts and foundations which supported us in 2022:

Anthony Alex
Artemis Charitable Foundations
Bright Funds Foundation
Doris Field
F B Laurence
Florian Settlement Charitable Trust
Gunner Lewis Vale Trust
Hobsons Charity
Hudson Charitable Trust
Leonard Curtis
Mary Robertson
P F Charitable
RZK Foundation

Our thanks also go to our many recruitment partners, in particular those listed below, who have continued to support our mission:

10,000 donors
ACLT
AME-BCT
Jain and Hindu Organ Donation Steering Group
Jaskomal Foundation
Kevin Karawa Leukaemia Trust
Love Hope Strength
Race Against Blood Cancer
Sue Harris Trust
Team Margot
Upahaar

Thank you to our transplant centres:

London Haematology, The London Clinic
Therapeutic Apheresis Service, Royal Hallamshire Hospital

Finally, special thanks go to our haematology and transfusion medicine consultant, DKMS Medical Advisor Dr Khaled El-Ghariani.

This is Vansh (left) meeting his donor Harshil in 2019. Some donors are lucky to have the opportunity to meet their patient after donation. This depends on international guidelines and exact circumstances will vary from country to country.

DKMS Foundation: trustees’ report for the year ended 31 December 2022

Preparation of report

As the company qualifies as small under section 383 of the Companies Act 2006, the strategic report required of medium and large companies under The Companies Act 2006 (Strategic Report and Director’s Report) Regulations 2013 is not required.

DKMS Foundation (referred to hereinafter as ‘DKMS UK’) is incorporated as a charitable company limited by guarantee and is a registered charity in England and Wales, and in Scotland. It is governed by its Memorandum and Articles of Association, and the work, management, finances and strategy of the Charity are overseen by a Board of Trustees, who are also the Company Directors.

DKMS UK is connected through common trustees to DKMS gemeinnützige GmbH (‘DKMS’), and its related charities.

The trustees who held office during the financial year and at the date of the report are set out on page 55.

A minimum of two trustees at any one time are required by the Articles of Association. There is no maximum limit required by the Articles. At every Annual General Meeting (AGM) one-third of the trustees retire by rotation, but are eligible for re-election. There is no restriction on the term of tenure as a Trustee. Trustees do not receive remuneration for their duties.

Purpose

DKMS UK’s charitable purposes are set out in its Memorandum of Association as follows: “The preservation and protection of good health and the relief of sickness of individuals who are suffering from any kind of blood cancer.”

Public benefit

DKMS UK raises awareness of blood cancers and blood disorders in the UK, including the life-changing impact of a diagnosis, in order that increasing numbers of the general public know about the need for more people to register as a potential blood stem cell donor. Increasing the number and diversity of potential blood stem cell donors is vital in increasing the life chances of blood cancer and disorder patients who need a blood stem cell transplant. At present, only 3% of the UK population are registered as donors compared to much higher levels in some other countries.

Registering more potential blood stem cell donors means that we are able to provide more second chances at life by finding and supporting an unrelated blood stem cell donor who can and will donate their stem cells for a patient in need of a life-saving blood stem cell transplant.

Through recruiting, registering and supporting blood stem cell donors to be part of life-saving treatments, we deliver significant public benefit to patients and their families and to the National Health Service, which arranges treatment and care for those patients.

The trustees review the aims, objectives and activities of DKMS UK each year, ensuring the Charity remains focused on its stated purpose. This report looks at what DKMS UK has achieved and the outcomes of its work in the reporting period.

The trustees have referred to the guidance contained in the Charity Commission’s general guidance on public benefit when reviewing the Charity’s aims and objectives and in planning its future activities. In particular, the trustees consider how planned activities will contribute to the aims and objectives that have been set.

The aims of DKMS UK are to:

Raise awareness of blood stem cell donation;
Increase the number and diversity of registered potential blood stem cell donors in the UK; and
Provide more second chances at life for those with blood cancer or blood disorders whose survival depends upon being matched with an unrelated blood stem cell donor.

Board and management operations and structure of Board of Trustees

The Board of Trustees meets twice a year to review DKMS UK’s work, finances and services, and to agree the strategic goals for the Charity.

DKMS Foundation: trustees’ report for the year ended 31 December 2022

Recruitment and appointment of new trustees

Trustees are appointed on the basis of their relevant skills and experience. The ongoing trustees are responsible for the induction of any new trustees, which involves an awareness of a Trustee’s responsibilities, the governing document, administrative procedures, the history, approach and current business plan of DKMS UK.

The trustees also make available a welcome pack to include copies of the previous year’s annual report and financial statements, a brief history of the charitable company and a copy of the governing document. The pack also includes a copy of the Charity Commission guidance ‘The essential Trustee: What you need to know. What you need to do.’

While DKMS UK is connected through common trustees to DKMS gemeinnützige GmbH (‘DKMS’), it continues to aim to recruit additional trustees that can broaden and support its representation in the UK.

Management and organisation

Day-to-day operations of the Charity and strategy implementation is delegated to the Country Manager supported by the Senior Leadership Team (SLT). In the absence of the Country Manager, Stephan Schumacher, Interim CEO oversees the work of the SLT.

The Senior Leadership Team comprises:

Head of Communications and Engagement Daniel Philipp Hoffmann
Head of Finance & Corporate Services Hasnein Alidina
Head of Fundraising Caroline Richardson
HR Manager Regina Salih

The Charity has an organisational salary structure based upon a job evaluation study and external salary benchmarking concluded in June 2023. New roles are assessed against the job evaluation criteria and placed in a corresponding grade in the structure.

The salary structure’s pay levels are reviewed at least annually by the Country Manager to ensure that salary scales are aligned with those for similar positions in the external market. A review of salaries normally takes place annually, and is usually implemented in January. If changes are to be made, staff are advised in writing of the amount and the date from which it takes effect. A salary review does not imply an increase and in making any pay award the review will be based on the organisation’s financial health and achievements.

With reference to the National Council of Voluntary Organisation’s 2014 inquiry into executive pay (NCVO, Report of the Inquiry into Charity Senior Executive Pay and Guidance for Trustees on Setting Remuneration), the Board of Trustees is committed to including the following information within its annual statutory report and financial statements:

A summary statement of the Charity’s remuneration policy and approach to senior executive pay.
Disclosures on the number of staff in receipt of more than £60,000 per annum (in bands of £10,000), and the collective total benefits (including pension payments and employer’s national insurance) paid to ‘key management personnel’ (which we have defined as the Senior Leadership Team), in line with the accounting Statement of Recommended Practice 2019 for charities. Given the Charity’s size, the Board of Trustees does not believe it is appropriate to disclose the actual/personal salary of any individual member of staff, including senior executives, to the public.
Disclosures on pensions and other staff benefits (see subsequent notes to the financial statements).

Related parties

The only related parties are considered to be the trustees and those connected with the trustees, including their close family, business and other charity interests. There have been no transactions with related parties, other than the reimbursement of reasonable travel expenses for the purposes of attendance at Board meetings and other relevant organisational activities.

Remuneration

Our approach to fundraising

We continue to uphold the highest standards in how we communicate with our fundraising donors and supporters and ensure that our fundraising practices meet the requirements of the recommended Codes of Practice.

We treat our donors and supporters with great respect and gratitude that befits a community of people and organisations that make our work possible.

In order to recruit and retain staff of the calibre it requires, DKMS UK’s pay policy is to remunerate staff at levels above the voluntary sector median rate, but below the private sector market rate.

DKMS Foundation: trustees’ report for the year ended 31 December 2022

Key aspects of our approach to fundraising include:

Registration with the Fundraising Regulator, which maintains the standards for charitable fundraising and ensures that fundraising is respectful, open, honest and accountable to the public. It also takes complaints about fundraising, investigates cases and adjudicates on fundraising practice.
Ensuring our fundraising approach is aligned with the Charity’s governing objectives.
We have a complaints policy, which outlines our commitment to resolving fundraising complaints as promptly and amicably as possible. It also sets out our process for handling any complaints received. As per our policy, complaints will be reported and referred to the Fundraising Regulator if a resolution with the complainant cannot be reached or if the complaint is about a breach of any aspect of the Code of Fundraising Practice.
In 2022 we did not receive any complaints across the organisation. Trustees are updated on a bi-annual basis with regards to the number of complaints we have handled in the year.
We raise funds through individual giving requests (cash appeals, regular donation asks and online giving), community, challenge events, corporate and trust fundraising.
We do not carry out any telephone, face-to-face or door-to-door fundraising.
We do not use third party agencies to make fundraising requests, although we do use them for fulfilment purposes, e.g. acquisition of charity place challenge events, processing direct debits or distribution of fundraising direct mail. In such situations, legal agreements are in place. In no other circumstance do we swap or share data and we never sell data.
All fundraising activity complies with the UK General Data Protection Regulation (GDPR) and associated legislation and guidance.
Promotional goods sent out for fundraising purposes, and use of our logo on external fundraising materials, is subject to approval. Official stationery, such as our letterhead, is never sent out for external use.

Risk assessment and management

DKMS UK operates a risk assessment and management framework that reviews major risk areas on a quarterly basis.

The Country Manager and individual members of the SLT take responsibility for the day-to-day management and oversight of the above risk areas. The trustees review the assessments and mitigating actions at their Board meetings and consider the following areas to be the major risks related to DKMS UK’s operations and activities.

Medical safety of donors during the blood stem cell collection process

Although the medical process and procedure for blood stem cell donation and collection is safe, well-established and regulated, there will always be some safety risks and DKMS UK acknowledges these and takes them seriously.

The risks to the safety of our donors before, during and after the donation process, as well as any risks to transplant patients from the collection of poor-quality stem cell product are managed and mitigated in the following ways:

Working in line with approved and regularly reviewed Standard Operating Procedures that comply with domestic and international standards and regulations, and that include clear identification and reporting mechanisms for Serious Adverse Events and Reactions and Quality Incidents.
Working only with experienced, trusted and appropriately regulated medical partners and services. These relationships in turn are governed via established legal contracts and service protocols and regular service reviews.
Ensuring a thorough quality assurance system is in place within the organisation, including compliance with the World Marrow Donor Association (WMDA) standards (qualification for which was achieved and approved in March 2021).
Ensuring ongoing training, support and continuing professional development for all staff involved in the blood stem cell registration and donation process.

DKMS Foundation: trustees’ report for the year ended 31 December 2022

Data management and protection

The collection, processing, storage and security of our blood stem cell donors’ personal data and genetic information is of paramount importance and so represents a major risk in the event of mismanagement, loss or misuse of that data.

The potential damage to individual donors through a data breach, let alone the damage to DKMS UK’s and the DKMS Group’s reputation and activities in working with patients, donors, supporters and stakeholders would be catastrophic.

Financial risks

There are a number of areas of financial risk faced by DKMS UK:

Failure to achieve budgeted income levels.
Inadequate financial controls or fraud.
Poor financial management, including credit risk management, pricing risk and foreign exchange and liquidity risks.

These risks are managed and mitigated in the following ways:

We manage and mitigate these risks through:

Adherence to and compliance with strong information security and data protection policies and practices throughout the whole DKMS Group.
Ensuring data processing and third parties and protocols are in place with suppliers and partners.
Regular training and reviews for staff, volunteers and donor registration partners.
Blood stem cell donor recruitment.

Effective and high-quality blood stem cell donor recruitment is essential to ensuring we meet the needs of patients and transplant centres looking for a match. If we fail to ensure we recruit sufficient numbers of donors with a diverse range of backgrounds, and also with accurate and regularly updated personal health and genetic information and contact details, then we risk not being able to save the lives of more blood cancer and blood disorder patients. We manage and mitigate this risk by ensuring we have:

Clear and compelling communications and explanations about the registration process and the need for blood stem cell donors.
Effective quality check and review processes.
Quality programmes to enhance the health and contact information we have on the priority groups among our blood stem cell donors.
A system for prioritisation for recruiting, retaining and supporting potential and actual blood stem cell donors.
Strong planning, budgeting and monitoring processes in relation to income streams, including fundraising.
Strong internal financial controls and data security.
Regular reviews of fraud risks.
Close interaction, support and cross-checking with the international financial management and controlling teams in Germany.
Vetting by DKMS Germany of international health services, registries and companies involved in stem cell transplantation, so that stringent assessments on credit risk are carried out and appropriate financial terms agreed for all DKMS companies within the Group.
Ensuring pricing of products and services is set at reasonable and affordable levels, that recognise the Group’s role as a healthcare service provider with a primary objective of saving lives. Pricing levels are based on a production cost structure and also acknowledge differences in international economies, as well as the need to ensure patient treatments are not jeopardised by costs.
Maintaining good cash flow and financial management systems in order to manage fluctuations in the major trading currencies in which DKMS UK deals.
Cash flow projections are prepared as part of the Charity’s strategic planning, while liquidity levels are monitored internally on a daily basis as well as reported to central management and trustees at each reporting period.
Adequate balances are maintained in all currencies to ensure sufficient funding is available to meet commitments.

DKMS Foundation: trustees’ report for the year ended 31 December 2022

Logistical and supply line business continuity and resilience

Ensuring we have reliable, efficient and cost-effective methods for transporting our swab packs, blood samples and collected blood stem cells is crucial to the successful achievement of our organisational goals and objectives to save more lives, as is having a well-stocked and maintained supply line, resources and medicines. To manage and mitigate the risks of business-critical supplies and logistical arrangements we have:

Financial review

Going concern

The Board of Trustees of the ultimate parent company approved an arrangement to continue funding DKMS UK’s main activities to meet all its liabilities from its principal, DKMS gemeinnützige GmbH for a period not less than 12 months from the date these financial statements are approved. Accordingly, the trustees continue to adopt a going concern basis in preparing the financial statements.

Implemented strong review processes for stock control and order processing.
Made alternative arrangements and contingency plans for business continuity and disaster recovery scenarios.
Developed contingency plans to provide for business periods where we are working at higher than normal levels of activity or volume (e.g. when running successful campaigns).

Effect on DKMS UK business activity and post Brexit and UK’s economic challenges

The company’s business activities in 2022 show positive results to budget and the trend is expected to continue for rest of the year with the company’s funding requirements expected to remain well within the amounts approved by the board for next three years.

The charitable company’s net current assets at 31 December 2022 were £2,253,427 (2021: £1,069,433). Further details regarding the adoption of the going concern basis can also be found in the Accounting Policies on page 33.

Financial results

In 2022 the UK economy witnessed a short period of economic turmoil. The UK economic outlook appears to be more positive and predictable since the last budget. However high and persistent level of inflation, after effects of Brexit, strikes and economic inactivity has resulted in very sharp cost increases. A significant part of these cost increases cannot be passed on and are therefore absorbed by the charity.

Post-balance sheet events

The UK Board approved a strategic project to increase registrations from diverse ethnic minority communities in India in 2023 and to extend it to the Republic of South Africa thereafter. This will help increase the number of registered donors from these communities and help find more matching donors for the Indian and African diaspora globally.

DKMS UK received donations totalling £3,603,214 (2021: £2,608,270) of which £1,951.981, (2021: £775,451) was donated funds, £1,651,233 (2021: £1,825,114) was donated services from DKMS in Germany and other income £nil (2021: £7,705).

The charity company’s net income for the year amounted to £1,046,701 (2021: £223,736) mainly from increase in Fundraising income. Activity levels in stem cell transplants in the year remained at similar levels as in prior year and generated income of £6,971,070 (2021: £6,381,655).

Reserves policy

DKMS UK’s aim is to gradually grow its unrestricted funds and achieve full financial independence. While the Charity is growing its income base and cash flow, it continues to receive funding for its main activities from its principal, DKMS gemeinnützige GmbH. The trustees have approved for this arrangement to continue for the foreseeable future and until DKMS UK becomes financially independent to meet all its liabilities for at least 12 months. As at 31 December 2022 DKMS UK’s unrestricted funds were £2,228,121 (2021: £1,181,420).

DKMS Foundation: trustees, report for the year ended 31 December 2022 Principol funding Trustees. responsibilities statement The Trustee5 (who a olso directors of DKMS Foundotion for the purposes (>f compony lowl ore responsible for preporing the trustee5' report and the finon¢iol statements In accordonce with opplieoble low ond United Kingdorn Accountin9 Standord5 (United Kingdom Generally Accepted Accounting Practice). In the period under review. DKMS UKS principol fundin9 ho5 come from donation5 from DKMS in Germony. In the meantime, the choritoble company continues to grow Its fee in¢ome from referral of potential blood stem cell donor5 ond manogement of peripherol blood stem cell or bone marrow collections ond establishing a broader bose of tsdditional funding sources to grow its voluntary donation inctsme. Company low r89uires the trustees to prepare fin¢Jncial stotements for each finoncial year Under compony law the trLJStees must not approve the financial stotements unless they are sot15fied that they give a true ond fair view of the stote of offairs of the charitoble company and of the incomin9 resources ond upplicution of resources. including the income ond Èxpenditure, of the charitable company for that period. The chority has also developed o fundraising Strote9y to roise additionol funding through new voluntary donations initiatives ond events. Futuro developments DKMS remoins on trock to increase the number of blood stem cell donotions to Èxceèd 500 within the next 2 yeors and continues odding new blood stem cell donors to the UK registei to support this tsim. In preporing these finoncial 5tatemÈnts. the trustees ore required to.. Recruitrnent must rernain turgeted. with o parti¢ular focus on those frorn ethnic minority communities. os those groups will further help increase our overoll number of matched donors, and move us closer to levelling up occess to tronsplantation. Select suitoble accounting policies and then opply them consistently", Observe the methods cjnd principles in the Chorities Stotement of RecomrnendÈd Proctice ISORPI., Makè judgments ond oc¢ounting estimotes thut are reasonable and prudent", and Prepore the financiol stotements on the soing concern basis unless it is inoppropriate tc> presume that the choritoble company will continije in operation. Fundroising work is planned to grow significantly over the next three yeor5 to support our expansion, with important areas for future growth bein9 community- based and volunteer-led progromrrie5. along with on exponded ¢orporote support pro9romme. Th15 SUPPOrt is vitol to achieve our oim of finding a matching donor for every stem cell tran5plont potient thot needs one and where required covering the costs of the transplunt. Disclosure o+ information to auditor¥ Eoch of the persons who ore trustees ot the time when this trustees report is opprc>ved has confirmed that.. Change of auditor$ Pricewoterhousecoopers LLC IPWCI resigned a5 auditors on 24 October 2022 ofter their proposol for si9nificontly higher than the rtste of inflation fee Increose wos not accepted by the Board of DKMS UK. PWC ¢tsnfirrned there were no other motters ¢onnected with their ceosing to hold office as auditors of the Foundotion thtst they considered need to be brought to the attention of the Foundotion's mÈrnbers or creditors. Sc> for os that trLJStee is owore. there is no relevont oudit information of which the charitable ¢ompany' ouditors are unowore, ond That trustee has tcjken oll the step5 thot OU9ht to hove been taken as o trustee in order to be owore of any relevtsnt ttudit information ond to estoblish that the chorittsble Gompanys ouditors ore owure of that informtstion The Board appointed Mozors LLP auditors on 12 December 2022. This report was opproved by the trustees on 17July ond Sl9ned on their beholf on 21 September 2023 by.. Jerome-olivèr Quella Trus Chang• of trust••6 and dir•etors Sirko Geist, CFO ond Director resi9ned on 18 October 2022 following his oppointment as Executive position within the DKMS Group in Germony. Jér&me-Oliver Quello wos appointed os CFO and Dirèctor tsn 01 December 2022. 25

Independent auditors’ report to the members and trustees of DKMS Foundation

Opinion

In our opinion, DKMS Foundation’s financial statements (the ‘financial statements’):

Give a true and fair view of the state of the charitable company’s affairs as at 31 December 2022 and of its incoming resources and application of resources, including its income and expenditure, and cash flows for the year then ended;
Have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, comprising FRS 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’, and applicable law); and
Have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of The Charities Accounts (Scotland) Regulations 2006 (as amended).

We have audited the financial statements, included within the Annual Report and Financial Statements (the ‘Annual Report’), which comprise: the balance sheet as at 31 December 2022; the statement of financial activities (incorporating income and expenditure account) and the statement of cashflows for the year then ended; and the notes to the financial statements, which include a description of the significant accounting policies.

Independence

We remained independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, which includes the FRC’s Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements.

Conclusions relating to going concern

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company’s ability to continue as a going concern for a period of at least twelve months from the date on which the financial statements are authorised for issue.

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

However, because not all future events or conditions can be predicted, this conclusion is not a guarantee as to the charitable company’s ability to continue as a going concern.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (‘ISAs (UK)’) and applicable law. Our responsibilities under ISAs (UK) are further described in the Auditors’ responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independent auditors’ report to the members and trustees of DKMS Foundation

Reporting on other information

The other information comprises all of the information in the Annual Report other than the financial statements and our auditors’ report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, accordingly, we do not express an audit opinion or, except to the extent otherwise explicitly stated in this report, any form of assurance thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify an apparent material inconsistency or material misstatement, we are required to perform procedures to conclude whether there is a material misstatement of the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report based on these responsibilities.

With respect to the Trustees’ Report, we also considered whether the disclosures required by the UK Companies Act 2006 have been included.

Based on our work undertaken in the course of the audit, the Companies Act 2006 and The Charities Accounts (Scotland) Regulations 2006 (as amended) require us also to report certain opinions and matters as described on the next page.

Trustees’ Report

In our opinion, based on the work undertaken in the course of the audit the information given in the Trustees’ Report for the financial year for which the financial statements are prepared is consistent with the financial statements and the Trustees’ Report have been prepared in accordance with applicable legal requirements.

In addition, in light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we are required to report if we have identified any material misstatements in the Trustees’ Report. We have nothing to report in this respect.

Responsibilities for the financial statements and the audit

Responsibilities of the trustees for the financial statements

As explained more fully in the trustees’ responsibilities statement, the trustees are responsible for the preparation of the financial statements in accordance with the applicable framework and for being satisfied that they give a true and fair view. The trustees are also responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company’s ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Independent auditors’ report to the members and trustees of DKMS Foundation

Auditors’ responsibilities for the audit of the financial statements

We have been appointed as auditors under section 44(1) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Acts and relevant regulations made or having effect there under.

Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of The Charities Accounts (Scotland) Regulations 2006 (as amended). We evaluated management’s incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls), and determined that the principal risks were related to manipulation of financial performance. Audit procedures performed included:

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors’ report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Based on our understanding of the charitable company and industry, we identified that the principal risks of non-compliance with laws and regulations related to Health and Safety regulations and employment law, and we considered the extent to which non-compliance might have a material effect on the financial statements. We also considered those laws and regulations that have a direct impact on the financial statements such as the

Enquiries of management around known or suspected instances of non-compliance with laws and regulations, claims, litigation, and instances of fraud;
Understanding of management’s controls designed to prevent and detect irregularities;
Review of board minutes;
Identifying and testing journal entries to assess whether any of the journals appeared unusual, for example unexpected account combinations impacting revenue; and
Incorporating an element of unpredictability into our testing plan.

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

A further description of our responsibilities for the audit of the financial statements is located on the FRC’s website at: www.frc.org.uk/ auditorsresponsibilities. This description forms part of our auditors’ report.

Independent auditors. report to the members and trustees of DKMS Foundation Use of this report Entitlement to exemptions Thi5 report, including the opinion5. hos been prepored fc>r ond only for the ¢horitablÈ ¢(>rnponys members and trustees 05 a body in accordon¢e with section 44111 1¢) of the Chorities oncl Trustee Investment Iscotlondl Act 2005 ond the Companies Act 2006 ond re9ulotions mode under those Acts Iregulotion 10 of The Chorities Accounts Iscotlondl Re9ulations 2006 los omended} and Chopter 3 of Port 16 of the C(>mp¢Jnies Act 20001 ond for no other purpose. We do n(>t. in giving these opinions. OCCÈPt or assume responsibility for ony other purpose or to ony other person to whorn this report is shown or Into whose honé5 It moy come sove where expressly ogreed by our prior Consent in writing. Under the Componies Act 2006 we ore required to repc>rt to you if. in our opinion. the trustees were not entitled to.. prepare finoncial stoternents in accordanee with the smoll componies, regime ond toke odvantoge of the smoll cornponys exemption from preparing 0 Strategic Report. We hove no exceptions to report arising from this responsibility. Ni¢olo Wokefield (Senior Statutory Auditor) for and on beholf of Mozars LLP Chartered Accountants ond Strjtutory Auditors, Sutton. Surrey Other required reporting Motters on which we are required to report by exception Under the Companies Act 2006 ond The Chorities Accounts Iscotlondl Regulotions 2006 las omended} we ore req¢Jired to report to you if. in our opinion.. 4September 2023 We hove not obtained oll the informotion tsnd explonations we require for our audit". or Adequote ond proper occounting records hove not been kept or returns odequote for our oudit have not been received from bran¢hes not visited by us.. or Certoin disclosures of trustÈes' remijneration spÈcified by low are not mode.. or The financial stotements are not in agreement with the cjceounting records and returns. We hove no Èxception5 to report orising from this responsibility. 29

DKMS Foundation: Statement of financial activities

(Incorporating income and expenditure account) for the year 31 December 2022

Unrestricted funds 2022	Unrestricted funds 2022	Total funds 2022	Total funds 2021
Note	£	£	£
Income from Donations and legacies 2 Charitable activities 3 Total Income Expenditure on Raising funds 4 Charitable activities 5, 6 and 9 7, 18 Net Income/(expenditure) before other recognised gains and losses Reconciliation of funds Total funds brought forward Total funds carried forward	3,603,214 6,971,070 10,574,284 1,188,144 8,339,439 9,527,583 1,046,701 1,046,701 1,181,420 2,228,121	3,603,214 6,971,070 10,574,284 1,188,144 8,339,439 9,527,583 1,046,701 1,046,701 1,181,420 2,228,121	2,608,270 6,381,655
			8,989,925
			521,982 8,244,207
			8,766,189
			223,736
			223,736 957,684
			1,181,420

All activities relate to continuing operations.

The notes on pages 16 to 28 form part of these financial statements.

ati As at 31 December 2022 2022 2021 Not¢ FiJt¢d Tungible assets Investment5 12 59.165 111,986 13 59J66 111,987 C¥rront a88rt6 Inventory Debtors 14 285.015 180,086 15 1.313149 i.In,084 Cash ot bonk and in hond 21 1.749.940 1.017.n3 3.348J04 2.368.893 Cr•ditor8: amount$ l11Th9 du• wlthln on* ar 16 (1.179.149) (L299.460) Net current asset5 1168,955 1.069,433 Net assets 2,228.121 1,181,420 eharity Fundt Unrestricted funds 18 2.228.121 1,181,420 Toknl fund41 19 2.228.121 1.181.420 The ¢ompony's financial stotements hove been prepared in accordonce with the provisions applicoble to componies subject to the small cornponies re9irne. The trustees consider thot the compony is entitled to exemption from the requirement to hove on oudit under the provisions of section 477 of thè Componies Att 20061.the Aet") and rnembers have not required the compony to obtoin on oudit ftsr the yetsr in question in accordonee with section 476 of the Act. However, an oudit is required in accordance with se¢tion 144 tsf the Chorities Act 2011. The trustees ocknowled9e their responsibilities for complying with the requirements of the Act with respect to accountin9 records ond the preporotion of finonciol stotements. The finonciol stotemÈnts were approved ond outhorised for issue by the trustees on 17 July ond si9ned on their beholf on 21 September 2023 bv.. Jér6mè-OliverQuello Trustee The notès on poges 16 to 28 form port of these fing ial statements. 31

DKMS Foundation: Statement of cash flows

For the year ended 31 December 2022

	2022	2021
Note	£	£
Cash fows from operating activities Net cash provided by operating activities 20 Cash fows from investing activities Purchase of tangible fxed assets Net cash used in investing activities Change in cash and cash equivalents in the year Cash and cash equivalents brought forward Cash and cash equivalents carried forward 21	749,434 (17,217) (17,217) 732,217 1,017,723 1,749,940	281,170
		(35,950)
		(35,950)
		245,820 771,903
		1,017,723

The notes on pages 16 to 28 form part of these financial statements.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

01. Accounting Policies

1.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

DKMS Foundation meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The financial statements are presented in pound sterling (£).

1.2 Going concern

1.3 Company status

The charitable company is limited by guarantee. The members of the company are the trustees named on page 55. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company.

1.4 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of the company and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the company for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

The trustees of the ultimate parent company review the company’s activities and 3 year business plan each year and establish and approve funding level required to enable the company to achieve its goals and meet its business commitments and liabilities.

The trustees have approved arrangement to continue funding the charitable company’s main activities from its principal, DKMS Gemeinnutzige GmbH until the company becomes financially independent to meet all its liabilities for a period not less than twelve months from the date these financial statements are approved. Accordingly, they continue to adopt going concern basis in preparing the financial statements.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

1.5 Income

All income is recognised once the charitable company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably. Money donation income is recognised when the income is credited into the company’s account and revenue for clinical services is recognised after services are delivered.

Donated services or facilities are recognised when the charitable company has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use by the charitable company of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102). General volunteer time is not recognised. Further information about volunteer contribution is included in the trustees’ report.

On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the charitable company which is the amount the charitable company would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Governance costs include those costs associated with meeting the constitutional and statutory requirements of the charitable company and include the audit fees and costs linked to the strategic management of the charitable company.
All costs are allocated between the expenditure categories of the statement of financial activities on a basis designed to reflect the use of the resource. Costs relating to a particular activity are allocated directly; others are apportioned on an appropriate basis. Staff costs are allocated based on staff numbers, premises costs are allocated based on space occupied.

1.7 Tangible fixed assets and depreciation

Tangible fixed assets are carried at cost, net of accumulated depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Leasehold improvements - over period of lease (4 years) straight line.
Office equipment - 33.33% per annum straight line.
Computer equipment - 33.33% per annum straight line.

1.6 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to make payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis. All expenses including support costs and governance costs are allocated to the applicable expenditure headings:

Costs of generating funds comprise the costs associated with attracting voluntary income.
Charitable expenditure comprises those costs incurred by the charitable company in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

1.8 Investments

Investments are a form of basic financial instrument and are initially recognised at their transaction value. Investments in subsidiary companies are stated at cost less diminution in value.

1.9 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the company; this is normally upon notification of the interest paid or payable by the Bank.

1.10 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.11 Cash at bank and in hand

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.12 Creditors and provisions

Creditors and provisions are recognised where the charitable company has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

1.14 Financial instruments

The charitable company has applied Sections 11 and 12 of (FRS 102) in respect of financial instruments.

Financial assets and financial liabilities are recognised when the charitable company becomes party to the contractual provisions of the instrument. Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charitable company after deducting all of its liabilities.

The charitable company’s policies for its major classes of financial assets and financial liabilities are set out below.

Financial assets

Basic financial assets, including trade and other debtors, cash and bank balances, related charity working capital balances, and related charity financing are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.

Such assets are subsequently carried at amortised cost using the effective interest method, less any impairment.

1.13 Pensions

The charitable company operates a defined contribution pension scheme and the pension charge represents the amount payable by the charitable company in respect of the year.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

Financial liabilities

Basic financial liabilities, including trade and other creditors, bank loans and loans from related charities, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Impairment of financial assets

Financial assets measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the profit and loss account.

Derecognition of financial assets and financial liabilities

Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) despite having retained some significant risks and rewards of ownership, control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

Critical accounting estimates and areas of judgment

Management does not consider there to be any key judgements or estimates made in the preparation of the financial statements.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between the asset’s carrying amount and the best estimate of the amount the charitable company would receive for the asset if it were to be sold at the reporting date.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between the asset’s carrying amount and the present value of estimated cash flows discounted at the asset’s original effective interest rate. If the financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

02. Donations and legacies

	Unrestricted funds 2022	Total funds 2022	Total funds 2021
	£	£	£
Donation income International donation income Funding for donor recruitment activities from DKMS Gemeinnutzige GmbH Other income Total donations and legacies Total 2021	1,932,099 19,882 1,651,233 - 3,603,214 2,608,270	1,932,099 19,882 1,651,233 - 3,603,214 2,608,270	475,451 300,000 1,825,114 7,705 2,608,270

03. Charitable activities

	Unrestricted funds 2022	Total funds 2022	Total funds 2021
	£	£	£
Income from service provision Total 2021	6,971,070 6,381,655	6,971,070 6,381,655	6,381,655

In the year ended 31 December 2022 and 2021 all income related to unrestricted funds.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

04. Raising funds

	Unrestricted funds 2022	Total funds 2022	Total funds 2021
	£	£	£
Salaries, national insurance and pensions Other staff costs and training Premises costs Publicity & Awareness costs Postage, support and stationery Other admin costs Travel costs (Gain)/Loss on foreign exchange Depreciation Total 2021	336,699 27,301 60,032 626,982 1,593 130,313 4,795 (8,786) 9,215 1,188,144 521,982	336,699 27,301 60,032 626,982 1,593 130,313 4,795 (8,786) 9,215 1,188,144 521,982	333,167 10,455 58,061 9,341 1,794 89,671 272 10,739 8,482
			521,982

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

05. Direct costs

Recruitment of Donors	Recruitment of Donors	Raising Awareness	Donor Request Management	Total 2022	Total 2021
	£	£	£	£	£
Other direct costs Other staff costs and training Premises cost Publicity cost (Gain)/Loss on foreign exchange Postage, support and stationery Travel costs Donor typing costs Salaries, national insurance and pensions Depreciation Total 2021	237,726 262 65,465 65,819 (9,348) 197,626 14,866 1,651,232 241,453 9,805 2,474,906 2,658,100	129,058 47,001 112,157 250,538 (16,026) 288,543 3,071 - 372,823 16,809 1,203,974 1,203,574	2,384,558 177 114,461 (48,576) (18,697) 117,002 33,522 - 632,961 19,611 3,235,019 3,371,506	2,751,342 47,440 292,083 267,781 (44,071) 603,171 51,459 1,651,232 1,247,237 46,225 6,913,899 7,233,180	2,920,685 23,121 282,422 289,522 53,867 582,477 2,080 1,741,345 1,295,116 42,545
					7,233,180

In the year ended 31 December 2022 and 2021 all costs of direct charitable activities related to unrestricted funds.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

06. Support costs

Recruitment of Donors	Recruitment of Donors	Raising Awareness	Donor Request Management	Total 2022	Total 2021
	£	£	£	£	£
Legal and professional fees (Gain)/Loss on foreign exchange Other staff cots and training Premises costs Travel costs Other support costs Postage, Support and stationery Admin costs Salaries, national insurance and pensions Depreciation Total 2022 Total 2021	11,669 (2,952) 37,400 21,727 4,806 39,392 335 718 177,270 3,096	19,989 (5,061) 64,114 37,218 8,239 67,529 574 1,232 303,891 5,308 503,033 354,464	19,785 (5,904) 74,799 36,837 9,612 78,785 669 1,437 354,539 6,193 576,752 405,384	51,443 (13,917) 176,313 95,782 22,657 185,706 1,578 3,387 835,700 14,597 1,373,246 966,640	26,013 17,011 60,936 92,652 319 87,779 4,447 9,588 654,460 13,435
	293,461				966,640
	206,792

In the year ended 31 December 2022 and 2021 all support related to unrestricted funds.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

07. Analysis of expenditure by expenditure type

	Staff Costs 2022	Depreciation 2022	Other Costs 2022	Total 2022	Total 2021
	£	£	£	£	£
Expenditure on raising voluntary income Costs of raising funds Recruitment of donors Raising awareness Donor request management Charitable activities Expenditure on governance Total 2022 Total 2021	336,699 336,699 418,722 676,714 987,500 2,082,936 - 2,419,635 2,282,743	9,215 9,215 12,902 22,117 25,804 60,823 - 70,038 64,461	842,230 842,230 2,336,744 1,008,176 2,798,466 6,143,386 52,294 7,037,910 6,418,985	1,188,144 1,188,144 2,768,368 1,707,007 3,811,770 8,287,145 52,294 9,527,583 8,766,189	628,834
					628,834
					1,123,868 3,192,209 3,776,891
					8,092,968
					44,387 8,766,189

Expenditure on raising voluntary income has not been allocated to specific activities as all costs relate to general charitable activities.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

08. Analysis of expenditure by activities

	Activities undertaken directly 2022	Support costs 2022	Total 2022	Total 2021
	£	£	£	£
Recruitment of donors Raising awareness Donor request management Total 2022 Total 2021	2,474,906 1,203,974 3,235,019 6,913,899 7,157,735	293,461 503,033 576,752 1,373,246 935,233	2,768,367 1,707,007 3,811,771 8,287,145 8,092,968	1,123,869 3,192,209 3,776,890 8,092,968

In the year ended 31 December 2022 and 2021 all costs of direct charitable activities related to unrestricted funds.

09. Governance costs

	Unrestricted funds 2022	Total funds 2022	Total funds 2021
	£	£	£
Auditors' remuneration Legal and professional fees Total	27,600 24,694 52,294	27,600 24,694 52,294	23,000 21,387
			44,387

In the year ended 31 December 2022 and 2021 all governance costs related to unrestricted funds.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

10. Net income

This is stated after charging:

	2022	2021
	£	£
Depreciation of tangible fxed assets - Owned by the charity Auditors’ remuneration - audit	70,038 27,600	64,719 23,000
- Non-audit services Taxation advice	21,221	15,000

During the year, no trustees received any remuneration (2021- £Nil). During the year, no trustees received any benefits in kind (2021 - £Nil). During the year, no trustees received any reimbursement of expenses (2021 - £Nil).

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

11. Staff Costs

Staff costs were as follows:

	2022	2021
	£	£
Salaries Social security costs Pension costs Total	2,198,589 235,156 80,122 2,513,867	1,992,059 201,512 82,196
		2,275,767

The average monthly number of employees was: 51 (2021: 50) and the average monthly number of employees during the year.

Full time equivalents was as follows (including part-time and fixed period temporary staff):

	2022	2021
	No.	No.
Donor recruitment Fundraising Communications Medical Administration Total	7 5 8 16 15 51	7 5 12 14 12
		50

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

The number of higher paid employees was:

	2022	2021
	No.	No.
In the band £60,001 - £70,000 In the band £70,001 - £80,000 In the band £80,001 - £90,000 In the band £90,001 - £100,000 In the band £100,001 - £110,000 In the band £110,001 - £120,000 In the band £120,001 - £130,000 In the band £130,001 - £140,000 In the band £140,001 - £150,000 In the band £150,001 - £160,000 Total	2 2 0 1 0 0 1 0 0 1 7	2 1 1 0 0 0 1 0 0 0
		5

The charitable company trustees were not paid nor received any other benefits from employment with the charitable company in the year (2021: £Nil) neither were they reimbursed expenses during the year (2021: £Nil). No charitable company trustee received payment for professional or other services supplied to the charitable company (2021: £Nil).

The key management personnel of the charitable company are the trustees, the Chief Executive Officer and the heads of departments. There are 6 heads of department (2021: 6), four of whom received remuneration in excess of £60,000 during the year (2021: 5). The total employee benefits of the key management personnel of the charitable company were £590,985 (2021: £571,266).

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

12. Tangible assets

	Offce Equipment	Computer Equipment	Leasehold Improvements	Total
Cost	£	£	£	£
At 1 January 2022 Additions Disposals At 31 December 2022 Accumulated Depreciation At 1 January 2022 Charge for the year Release on disposal At 31 December 2022	70,434 999 (1,633) 69,800 56,666 6,442 (1,633) 61,475	171,328 16,218 (20,673) 166,873 128,437 30,399 (20,673) 138,163	228,855 - - 228,855 173,528 33,197 - 206,725	470,617 17,217 (22,306)
				465,528
				358,631 70,038 (22,306)
				406,363
Net book value
At 31 December 2022	8,325	28,710	22,130	59,165
At 31 December 2021	13,768	42,891	55,327	111,986

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

13. Investments

Shares in GroupUndertakings	Shares in GroupUndertakings
	£
Costs and net book value
At 31 December 2022 and 31 December 2021	1

The company’s wholly owned subsidiary, Delete Blood Cancer UK Marketing Limited, registered at Ashburnham House, Castle Row, Horticultural Place, London W4 4JQ is a dormant company. Its net liability position at 31 December 2022 £10,245 (2021: £10,245) is represented by amounts due to parent company and is fully provided for in the accounts of the parent company.

14. Inventory

Inventory costs were as follows:

	2022	2021
	£	£
Materials stock Work in progress costs Total	241,509 43,506 285,015	155,634 24,452
		180,086

Inventories are valued at lower of cost and net realisable value. Work in progress costs are reimbursable costs incurred for active stem cell collections awaiting to be billed.

15. Debtors

15. Debtors
	2022	2021
	£	£
Due within one year Trade debtors Amounts owed by group undertakings Amounts owed by related charity Other debtors Prepayments and accrued income Total	1,062,565 10,245 36,735 5,621 197,983 1,313,149	870,208 10,245 110,005 1,245 179,381
		1,171,084

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

16. Creditors: Amounts falling due within one year

	2022	2021
	£	£
Trade creditors Amounts owed to related charity Other creditors Other taxation and social security Accruals Total 17. Financial instruments	385,315 59,050 63,401 67,672 603,711 1,179,149 2022	349,404 30,807 22,217 62,586 834,446
		1,299,460
		2021
	£	£
Financial assets Financial assets that are debt instruments measured at amortised cost Financial liabilities Financial liabilities measured at amortised cost Total	1,115,166 (444,365) 670,801	991,703 (380,211)
		611,492

Financial assets measured at amortised cost include trade debtors, amounts owed by group companies, other debtors and amounts owed by related charity.

Financial liabilities include trade creditors and amounts owed to a related charity.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

18. Summary of funds

	2022	2021
	£	£
At 1 January Income for year Resource expended At 31 December	1,181,420 10,574,284 (9,527,583) 2,228,121	957,684 8,989,925 (8,766,189)
		1,181,420

19. Analysis of net assets between funds

Analysis of net assets between funds - current year:

	Unrestricted funds 2022	Total funds 2022
	£	£
Tangible fxed assets Fixed asset investments Current assets Creditors due within one year Total	59,165 1 3,348,104 (1,179,149) 2,228,121	59,165 1 3,348,104 (1,179,149)
		2,228,121

Analysis of net assets between funds - prior year:

	Unrestricted funds 2021	Total funds 2021
	£	£
Tangible fxed assets Fixed asset investments Current assets Creditors due within one year Total	111,986 1 2,368,893 (1,299,460) 1,181,420	111,986 1 2,368,893 (1,299,460)
		1,181,420

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

20. Reconciliation of net movement in funds to net cash flow from operating activities

	2022	2021
	£	£
Net income/(expenditure) for the year (as per Statement of Financial activities) Adjustment for Depreciation charges (Increase)/Decrease in debtors (Decrease) in creditors (Increase) in Inventory Total	1,046,701 70,038 (142,065) (120,311) (104,929) 749,434	223,736 64,461 706,925 (677,537) (35,815)
		281,770

21. Analysis of cash and cash equivalents

	2022	2021
	£	£
Cash at bank in hand Total	1,749,940 1,749,940	1,017,723
		1,017,723

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

22. Operating lease commitments

At 31 December 2022 the total of the charity’s future minimum lease payments under non-cancellable operating leases was:

	2022	2021
	£	£
Within 1 year Between 2 and 5 years Over 5 years Total	214,541 3,097 - 217,638	285,022 217,638 -
		502,660

Lease payments recognised as an expense amounted to £282,183 (2021: £282,183).

The company entered into a new 4 year lease ending 30 September 2023 for its current office premises at annual rent of £281,925 including a 6 month rent-free period at the start of the lease and a 3 year lease ending October 2024 for purchase of operating equipment at annual rent of £3,097.

The Superior leaseholders are in negotiations with the freehold landlords for renewal of their lease for these premises and have indicated to DKMS that they would correspondingly offer the charitable company a new lease for a further period. Negotiations have progressed positively and are at final stages.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

23. Related party transactions

The company has taken advantage of the exemption contained in FRS 102 section 33 “Related Party Disclosures” from disclosing transactions with entities which are a wholly owned part of the group.

Transactions with other related parties are as follows:

Name	Transaction	Amount	Amount	Amount due from/	Amount due from/
(relationship)				(to) related party
		2022	2021	2022	2021
		£	£	£	£
DKMS	Donated	1,651,233	1,825,114	-	83,930
Gemeinnutzige GmbH	services
(Common Trustees)
DKMS	Intercompany	349,474	249,463	(52,617)	(30,141)
Gemeinnutzige GmbH	recharges
(Common Trustees)
DKMS Life Science Lab	Intercompany	-	161	-	-
(Common Trustees)	service provision
DKMS Registry	Intercompany	77,119	54,339	(5,676)	(7,050)
Gemeinnutzige GmbH	service provision
DKMS USA	Intercompany	68,120	667	(744)	(667)
(Common Trustees)	service provision
DKMS USA	International money	19,882	300,000	-	-
(Common Trustees)	donation
DKMS BMST	Intercompany	-	-	11,785	11,785
(India)	support services
DKMS Foundation NPC	Intercompany	38,310	14,290	24,950	14,290
(South Africa)	serviceprovision

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2022

Amounts owed to related parties are unsecured, interest free and due for repayment within one year.

DKMS Gemeinnutzige GmbH is the Controlling company and exercises full control over the charitable company through its common trustees who are also directors of the company. The controlling company recharges the charitable company actual or appropriately apportioned costs it incurs in providing support to the latter.

The controlling company DKMS Gemeinnutzige GmbH entered into a contract with DKMS Life Science Lab whereby DKMS Foundation receives typing services for no consideration from 01 January 2021.

DKMS Life Science Lab is one of the leading HLA laboratories and provides this service for all DKMS entities.

24. Post balance sheet events

The UK Board approved a strategic project to increase registrations from diverse ethic minority communities in India in 2023 and to extend it to the Republic of South Africa thereafter. This will help increase the number of registered donors from these communities and help find more matching donors for the Indian and African diaspora globally.

25. Controlling party

The trustees are the immediate controlling party and DKMS Gemeinnutzige GmbH is the ultimate parent. The principal address of the ultimate parent is Kressbach 1, 72072 Tubingen, Germany.

Copies of the group financial statements are available at www.dkms.de.

Ways you can support us

Organise a donor registration event

Organise an event to encourage your friends, family or colleagues to register as potential blood stem cell donors.

Create a bespoke partnership

DKMS can provide your company with networking and marketing opportunities aligned with our purposes and shared values.

Payroll giving

Donate to DKMS through your company’s Payroll Giving Scheme if employees are paid through PAYE.

Fundraising events

Whether holding a bake sale, organising a music night or giving up a vice, every penny you raise helps in the fight against blood cancer.

Daredevil challenges

If you fancy standing on top of a plane, jumping out of one, or filling your run with obstacles, we have something for everyone.

The 2K Club

Join our club of corporate supporters whose contribution goes towards helping the more than 2,000 people in the UK searching for a matching blood stem cell donor each year.

Giving in memory

Many people choose to remember a loved one by fundraising for DKMS. We’ll help you through the process to make sure their memory lives on through our work.

Trustees

Dr E Neujahr B J Abel S Geist J-O Quella Dr A H Schmidt S Schumacher

Principal staff

Stephan Schumacher, Country Manager, UK

Registered company number

105,703

Transplants for people in need*

11.7m

Potential donors registered*

08151279 (England & Wales)

Charity registered number

1150056 (England & Wales)

SC046917 (Scotland)

Registered office

Ashburnham House, Castle Row, Horticultural Place London W4 4JQ

21

Lifesaving blood stem cell donations each day*

*Global DKMS statistics as of 31 December 2022

Company secretary

B J Abel

Independent auditors

Mazars LLP 6 Sutton Plaza Sutton Court Road Sutton Surrey SM1 4FS

Bankers

Barclays Bank plc 74 Shepherds Bush Green Commerzbank AG Shepherds Bush 30 Gresham Street London W12 8QB London EC2V 7PG

DKMS is the trading name of DKMS Foundation, a company limited by guarantee registered in England and Wales (08151279) and a charity registered in England and Wales (1150056) and Scotland (SC046917).

2022-12-31-accounts

Impact Report and Financial Statements

Our Vision

Our Mission

Our Purpose

Contents

Country Manager’s introduction

01 Daniel’s blood cancer diagnosis

Blood cancer is the fifth most common cancer in the UK

The search 02 for a match

Over 300 in-person donation events in 2022

£40 to register each new donor

Covering 03 costs

Charity of the Year: Education Authority Music Service, Northern Ireland

What DKMS can achieve with your financial support

Campaigns

What do you want to be when you grow up?:

Corporates - vital collaborations

Donor 04 evaluation

Our state-of-the-art laboratory

Donors on the DKMS UK register by ethnicity

Stem cell 05 donation

06 Daniel today

Thank you

DKMS Foundation: trustees’ report for the year ended 31 December 2022

Preparation of report

Purpose

Public benefit

Board and management operations and structure of Board of Trustees

DKMS Foundation: trustees’ report for the year ended 31 December 2022

Recruitment and appointment of new trustees

Management and organisation

Related parties

Remuneration

Our approach to fundraising

DKMS Foundation: trustees’ report for the year ended 31 December 2022

Risk assessment and management

Medical safety of donors during the blood stem cell collection process

DKMS Foundation: trustees’ report for the year ended 31 December 2022

Data management and protection

Financial risks

DKMS Foundation: trustees’ report for the year ended 31 December 2022

Logistical and supply line business continuity and resilience

Financial review

Going concern

Effect on DKMS UK business activity and post Brexit and UK’s economic challenges

Financial results

Post-balance sheet events

Reserves policy

Independent auditors’ report to the members and trustees of DKMS Foundation

Opinion

Independence

Conclusions relating to going concern

Basis for opinion

Independent auditors’ report to the members and trustees of DKMS Foundation

Reporting on other information

Trustees’ Report

Responsibilities for the financial statements and the audit

Responsibilities of the trustees for the financial statements

Independent auditors’ report to the members and trustees of DKMS Foundation

Auditors’ responsibilities for the audit of the financial statements

DKMS Foundation: Statement of financial activities

(Incorporating income and expenditure account) for the year 31 December 2022

DKMS Foundation: Statement of cash flows

For the year ended 31 December 2022

01. Accounting Policies

1.1 Basis of preparation of financial statements

1.2 Going concern

1.3 Company status

1.4 Fund accounting

1.5 Income

1.7 Tangible fixed assets and depreciation

1.6 Expenditure

1.8 Investments

1.9 Interest receivable

1.10 Debtors

1.11 Cash at bank and in hand

1.12 Creditors and provisions

1.14 Financial instruments

Financial assets